메뉴 건너뛰기




Volumn 59, Issue 9, 2016, Pages 1860-1870

The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes

Author keywords

Empagliflozin; Macroalbuminuria; Microalbuminuria; Sodium glucose cotransporter 2; Type 2 diabetes; Urine albumin to creatinine ratio

Indexed keywords

ALBUMIN; CREATININE; EMPAGLIFLOZIN; HEMOGLOBIN A1C; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; SLC5A2 PROTEIN, HUMAN;

EID: 84975153660     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-016-4008-2     Document Type: Article
Times cited : (160)

References (38)
  • 1
    • 84920272288 scopus 로고    scopus 로고
    • Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes
    • PID: 24786708
    • Molitch ME, Adler AI, Flyvbjerg A et al (2015) Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes. Kidney Int 87:20–30
    • (2015) Kidney Int , vol.87 , pp. 20-30
    • Molitch, M.E.1    Adler, A.I.2    Flyvbjerg, A.3
  • 2
    • 79953235256 scopus 로고    scopus 로고
    • Relation of albuminuria to angiographically determined coronary arterial narrowing in patients with and without type 2 diabetes mellitus and stable or suspected coronary artery disease
    • PID: 21324429
    • Rein P, Vonbank A, Saely CH et al (2011) Relation of albuminuria to angiographically determined coronary arterial narrowing in patients with and without type 2 diabetes mellitus and stable or suspected coronary artery disease. Am J Cardiol 107:1144–1148
    • (2011) Am J Cardiol , vol.107 , pp. 1144-1148
    • Rein, P.1    Vonbank, A.2    Saely, C.H.3
  • 3
    • 84922251376 scopus 로고    scopus 로고
    • Renal outcomes in patients with type 1 diabetes and macroalbuminuria
    • PID: 24925722
    • de Boer IH, Afkarian M, Rue TC et al (2014) Renal outcomes in patients with type 1 diabetes and macroalbuminuria. J Am Soc Nephrol 25:2342–2350
    • (2014) J Am Soc Nephrol , vol.25 , pp. 2342-2350
    • de Boer, I.H.1    Afkarian, M.2    Rue, T.C.3
  • 4
    • 59849097777 scopus 로고    scopus 로고
    • Insights into the regulation of renal hemodynamic function in diabetic mellitus
    • COI: 1:CAS:528:DC%2BD1cXhtlKqsbzI, PID: 18991597
    • Cherney DZ, Scholey JW, Miller JA (2008) Insights into the regulation of renal hemodynamic function in diabetic mellitus. Curr Diabetes Rev 4:280–290
    • (2008) Curr Diabetes Rev , vol.4 , pp. 280-290
    • Cherney, D.Z.1    Scholey, J.W.2    Miller, J.A.3
  • 5
    • 84863796440 scopus 로고    scopus 로고
    • Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers
    • PID: 22437412
    • Lambers Heerspink HJ, Holtkamp FA et al (2012) Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int 82:330–337
    • (2012) Kidney Int , vol.82 , pp. 330-337
    • Lambers Heerspink, H.J.1    Holtkamp, F.A.2
  • 6
    • 33845271259 scopus 로고    scopus 로고
    • Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up
    • PID: 17130264
    • Navarro-Diaz M, Serra A, Romero R et al (2006) Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up. J Am Soc Nephrol 17(Suppl 3):S213–S217
    • (2006) J Am Soc Nephrol , vol.17 , pp. S213-S217
    • Navarro-Diaz, M.1    Serra, A.2    Romero, R.3
  • 7
    • 84885954870 scopus 로고    scopus 로고
    • Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
    • COI: 1:CAS:528:DC%2BC2cXosFSks7k%3D, PID: 24622369
    • Roden M, Weng J, Eilbracht J et al (2013) Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 1:208–219
    • (2013) Lancet Diabetes Endocrinol , vol.1 , pp. 208-219
    • Roden, M.1    Weng, J.2    Eilbracht, J.3
  • 8
    • 84885952950 scopus 로고    scopus 로고
    • Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial
    • PID: 23963895
    • Häring HU, Merker L, Seewaldt-Becker E et al (2013) Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 36:3396–3404
    • (2013) Diabetes Care , vol.36 , pp. 3396-3404
    • Häring, H.U.1    Merker, L.2    Seewaldt-Becker, E.3
  • 9
    • 84901455931 scopus 로고    scopus 로고
    • Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial
    • PID: 24722494
    • Häring HU, Merker L, Seewaldt-Becker E et al (2014) Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 37:1650–1659
    • (2014) Diabetes Care , vol.37 , pp. 1650-1659
    • Häring, H.U.1    Merker, L.2    Seewaldt-Becker, E.3
  • 10
    • 84892477577 scopus 로고    scopus 로고
    • Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
    • COI: 1:CAS:528:DC%2BC2cXptFWgsQ%3D%3D, PID: 23906415
    • Kovacs CS, Seshiah V, Swallow R et al (2014) Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 16:147–158
    • (2014) Diabetes Obes Metab , vol.16 , pp. 147-158
    • Kovacs, C.S.1    Seshiah, V.2    Swallow, R.3
  • 11
    • 84893214045 scopus 로고    scopus 로고
    • The renal hemodynamic effect of SGLT2 inhibition in patients with type 1 diabetes
    • COI: 1:CAS:528:DC%2BC2cXitFSqtLg%3D, PID: 24334175
    • Cherney DZI, Perkins BA, Soleymanlou N et al (2014) The renal hemodynamic effect of SGLT2 inhibition in patients with type 1 diabetes. Circulation 129:587–597
    • (2014) Circulation , vol.129 , pp. 587-597
    • Cherney, D.Z.I.1    Perkins, B.A.2    Soleymanlou, N.3
  • 12
    • 84933523949 scopus 로고    scopus 로고
    • Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
    • PID: 25280671
    • Škrtić M, Yang GK, Perkins BA et al (2014) Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia 57:2599–2602
    • (2014) Diabetologia , vol.57 , pp. 2599-2602
    • Škrtić, M.1    Yang, G.K.2    Perkins, B.A.3
  • 13
    • 84880850027 scopus 로고    scopus 로고
    • Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
    • COI: 1:CAS:528:DC%2BC3sXhtFygsr%2FE, PID: 23668478
    • Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J (2013) Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15:853–862
    • (2013) Diabetes Obes Metab , vol.15 , pp. 853-862
    • Lambers Heerspink, H.J.1    de Zeeuw, D.2    Wie, L.3    Leslie, B.4    List, J.5
  • 14
    • 84908514103 scopus 로고    scopus 로고
    • Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes
    • COI: 1:CAS:528:DC%2BC2cXhvVKmtb%2FP, PID: 25360497
    • Cherney DZ, Perkins BA, Soleymanlou N et al (2014) Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. Kidney Int 86:1057–1058
    • (2014) Kidney Int , vol.86 , pp. 1057-1058
    • Cherney, D.Z.1    Perkins, B.A.2    Soleymanlou, N.3
  • 15
    • 84899961819 scopus 로고    scopus 로고
    • Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
    • COI: 1:CAS:528:DC%2BC2cXnslaqsbw%3D, PID: 24795251
    • Barnett AH, Mithal A, Manassie J et al (2014) Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2:369–384
    • (2014) Lancet Diabetes Endocrinol , vol.2 , pp. 369-384
    • Barnett, A.H.1    Mithal, A.2    Manassie, J.3
  • 16
    • 78149359262 scopus 로고    scopus 로고
    • Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial
    • PID: 21055801
    • de Zeeuw D, Agarwal R, Amdahl M et al (2010) Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 376:1543–1551
    • (2010) Lancet , vol.376 , pp. 1543-1551
    • de Zeeuw, D.1    Agarwal, R.2    Amdahl, M.3
  • 17
    • 84890476805 scopus 로고    scopus 로고
    • Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction
    • COI: 1:CAS:528:DC%2BC3sXhsl2ht7vN, PID: 24026560
    • Groop PH, Cooper ME, Perkovic V, Emser A, Woerle HJ, von Eynatten M (2013) Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 36:3460–3468
    • (2013) Diabetes Care , vol.36 , pp. 3460-3468
    • Groop, P.H.1    Cooper, M.E.2    Perkovic, V.3    Emser, A.4    Woerle, H.J.5    von Eynatten, M.6
  • 18
    • 84892588641 scopus 로고    scopus 로고
    • SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
    • COI: 1:CAS:528:DC%2BC2cXitleit7Y%3D, PID: 24226524
    • Vallon V, Gerasimova M, Rose MA et al (2014) SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 306:F194–F204
    • (2014) Am J Physiol Renal Physiol , vol.306 , pp. F194-F204
    • Vallon, V.1    Gerasimova, M.2    Rose, M.A.3
  • 19
    • 84902536157 scopus 로고    scopus 로고
    • Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats
    • COI: 1:CAS:528:DC%2BC2cXps1Ohsbc%3D, PID: 24533859
    • Tahara A, Kurosaki E, Yokono M et al (2014) Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. J Pharm Pharmacol 66:975–987
    • (2014) J Pharm Pharmacol , vol.66 , pp. 975-987
    • Tahara, A.1    Kurosaki, E.2    Yokono, M.3
  • 20
    • 56149087069 scopus 로고    scopus 로고
    • Phlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic rats
    • Malatiali S, Francis I, Barac-Nieto M (2008) Phlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic rats. Exp Diabetes Res 2008:305–403
    • (2008) Exp Diabetes Res , vol.2008 , pp. 305-403
    • Malatiali, S.1    Francis, I.2    Barac-Nieto, M.3
  • 21
    • 0035122471 scopus 로고    scopus 로고
    • Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095
    • COI: 1:CAS:528:DC%2BD3MXht1Snsrw%3D, PID: 11159708
    • Arakawa K, Ishihara T, Oku A et al (2001) Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095. Br J Pharmacol 132:578–586
    • (2001) Br J Pharmacol , vol.132 , pp. 578-586
    • Arakawa, K.1    Ishihara, T.2    Oku, A.3
  • 22
    • 84905238756 scopus 로고    scopus 로고
    • The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension
    • COI: 1:CAS:528:DC%2BC2cXhsFanu77O, PID: 24944269
    • Gembardt F, Bartaun C, Jarzebska N et al (2014) The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Am J Physiol Renal Physiol 307:F317–F325
    • (2014) Am J Physiol Renal Physiol , vol.307 , pp. F317-F325
    • Gembardt, F.1    Bartaun, C.2    Jarzebska, N.3
  • 23
    • 84897394040 scopus 로고    scopus 로고
    • Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
    • COI: 1:CAS:528:DC%2BC3sXhsFequr3L, PID: 24067431
    • Kohan DE, Fioretto P, Tang W, List JF (2014) Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85:962–971
    • (2014) Kidney Int , vol.85 , pp. 962-971
    • Kohan, D.E.1    Fioretto, P.2    Tang, W.3    List, J.F.4
  • 24
    • 84876311251 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
    • COI: 1:CAS:528:DC%2BC3sXlvVenu7c%3D, PID: 23464594
    • Yale JF, Bakris G, Cariou B et al (2013) Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 15:463–473
    • (2013) Diabetes Obes Metab , vol.15 , pp. 463-473
    • Yale, J.F.1    Bakris, G.2    Cariou, B.3
  • 25
  • 26
    • 84255185190 scopus 로고    scopus 로고
    • Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat
    • COI: 1:CAS:528:DC%2BC38XitVemsL4%3D, PID: 21940401
    • Thomson SC, Rieg T, Miracle C et al (2012) Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol 302:R75–R83
    • (2012) Am J Physiol Regul Integr Comp Physiol , vol.302 , pp. R75-R83
    • Thomson, S.C.1    Rieg, T.2    Miracle, C.3
  • 27
    • 84892959743 scopus 로고    scopus 로고
    • The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
    • PID: 24475922
    • Cherney DZI, Perkins BA, Soleymanlou N et al (2014) The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 13:28
    • (2014) Cardiovasc Diabetol , vol.13 , pp. 28
    • Cherney, D.Z.I.1    Perkins, B.A.2    Soleymanlou, N.3
  • 28
    • 84891856342 scopus 로고    scopus 로고
    • Long-term outcomes of Japanese type 2 diabetic patients with biopsy-proven diabetic nephropathy
    • COI: 1:CAS:528:DC%2BC3sXhsl2ht7fM, PID: 24089538
    • Shimizu M, Furuichi K, Toyama T et al (2013) Long-term outcomes of Japanese type 2 diabetic patients with biopsy-proven diabetic nephropathy. Diabetes Care 36:3655–3662
    • (2013) Diabetes Care , vol.36 , pp. 3655-3662
    • Shimizu, M.1    Furuichi, K.2    Toyama, T.3
  • 29
    • 84871369220 scopus 로고    scopus 로고
    • Sodium-glucose cotransporter inhibition prevents oxidative stress in the kidney of diabetic rats
    • PID: 23227274
    • Osorio H, Coronel I, Arellano A et al (2012) Sodium-glucose cotransporter inhibition prevents oxidative stress in the kidney of diabetic rats. Oxid Med Cell Longev 2012:542042
    • (2012) Oxid Med Cell Longev , vol.2012 , pp. 542042
    • Osorio, H.1    Coronel, I.2    Arellano, A.3
  • 30
    • 84873497173 scopus 로고    scopus 로고
    • Effects of SGLT2 inhibition in human kidney proximal tubular cells—renoprotection in diabetic nephropathy?
    • COI: 1:CAS:528:DC%2BC3sXivVOltrs%3D, PID: 23390498
    • Panchapakesan U, Pegg K, Gross S et al (2013) Effects of SGLT2 inhibition in human kidney proximal tubular cells—renoprotection in diabetic nephropathy? PLoS One 8, e54442
    • (2013) PLoS One , vol.8
    • Panchapakesan, U.1    Pegg, K.2    Gross, S.3
  • 31
    • 84903528312 scopus 로고    scopus 로고
    • Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice
    • PID: 24960177
    • Terami N, Ogawa D, Tachibana H et al (2014) Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One 9, e100777
    • (2014) PLoS One , vol.9
    • Terami, N.1    Ogawa, D.2    Tachibana, H.3
  • 32
    • 84920971105 scopus 로고    scopus 로고
    • Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus
    • COI: 1:CAS:528:DC%2BC2MXis12rtrY%3D, PID: 25377916
    • Lytvyn Y, Škrtić M, Yang GK, Yip PM, Perkins BA, Cherney DZ (2015) Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol 308:F77–F83
    • (2015) Am J Physiol Renal Physiol , vol.308 , pp. F77-F83
    • Lytvyn, Y.1    Škrtić, M.2    Yang, G.K.3    Yip, P.M.4    Perkins, B.A.5    Cherney, D.Z.6
  • 33
    • 84928743782 scopus 로고    scopus 로고
    • Uric acid as a biomarker and a therapeutic target in diabetes
    • PID: 25600084
    • Lytvyn Y, Perkins BA, Cherney DZ (2015) Uric acid as a biomarker and a therapeutic target in diabetes. Can J Diabetes 39:239–246
    • (2015) Can J Diabetes , vol.39 , pp. 239-246
    • Lytvyn, Y.1    Perkins, B.A.2    Cherney, D.Z.3
  • 34
    • 44049101711 scopus 로고    scopus 로고
    • Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan
    • COI: 1:CAS:528:DC%2BD1cXmtlOgs7Y%3D, PID: 18272844
    • Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G (2008) Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 19:999–1007
    • (2008) J Am Soc Nephrol , vol.19 , pp. 999-1007
    • Vogt, L.1    Waanders, F.2    Boomsma, F.3    de Zeeuw, D.4    Navis, G.5
  • 35
    • 0025027402 scopus 로고
    • Glomerular filtration rate in streptozotocin-induced diabetic rats. Role of exchangeable sodium, vasoactive hormones, and insulin therapy
    • COI: 1:CAS:528:DyaK3MXhsVSrtL4%3D, PID: 2170215
    • Allen TJ, Cooper ME, O’Brien RC, Bach LA, Jackson B, Jerums G (1990) Glomerular filtration rate in streptozotocin-induced diabetic rats. Role of exchangeable sodium, vasoactive hormones, and insulin therapy. Diabetes 39:1182–1190
    • (1990) Diabetes , vol.39 , pp. 1182-1190
    • Allen, T.J.1    Cooper, M.E.2    O’Brien, R.C.3    Bach, L.A.4    Jackson, B.5    Jerums, G.6
  • 36
    • 0023519539 scopus 로고
    • Elevated plasma atrial natriuretic peptide levels in diabetic rats. Potential mediator of hyperfiltration
    • COI: 1:CAS:528:DyaL2sXlslelsb8%3D, PID: 2957390
    • Ortola FV, Ballermann BJ, Anderson S, Mendez RE, Brenner BM (1987) Elevated plasma atrial natriuretic peptide levels in diabetic rats. Potential mediator of hyperfiltration. J Clin Invest 80:670–674
    • (1987) J Clin Invest , vol.80 , pp. 670-674
    • Ortola, F.V.1    Ballermann, B.J.2    Anderson, S.3    Mendez, R.E.4    Brenner, B.M.5
  • 37
    • 84878060305 scopus 로고    scopus 로고
    • Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats
    • COI: 1:CAS:528:DC%2BC3sXptlOgsL4%3D, PID: 23492941
    • Kojima N, Williams JM, Takahashi T, Miyata N, Roman RJ (2013) Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J Pharmacol Exp Ther 345:464–472
    • (2013) J Pharmacol Exp Ther , vol.345 , pp. 464-472
    • Kojima, N.1    Williams, J.M.2    Takahashi, T.3    Miyata, N.4    Roman, R.J.5
  • 38
    • 84939565970 scopus 로고    scopus 로고
    • Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes
    • COI: 1:CAS:528:DC%2BC2MXotVWgsLg%3D, PID: 25960304
    • Cooper ME, Perkovic V, McGill JB et al (2015) Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes. Am J Kidney Dis 66:441–449
    • (2015) Am J Kidney Dis , vol.66 , pp. 441-449
    • Cooper, M.E.1    Perkovic, V.2    McGill, J.B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.